Novel approach to the formulation of an Epstein-Barr virus antigen-based nasopharyngeal carcinoma vaccine

Lutzky, Viviana P., Corban, Monika, Heslop, Lea, Morrison, Leanne E., Crooks, Pauline, Hall, David F., Coman, William B., Thomson, Scott A. and Moss, Denis J. (2010) Novel approach to the formulation of an Epstein-Barr virus antigen-based nasopharyngeal carcinoma vaccine. Journal of Virology, 84 1: 407-417. doi:10.1128/JVI.01303-09


Author Lutzky, Viviana P.
Corban, Monika
Heslop, Lea
Morrison, Leanne E.
Crooks, Pauline
Hall, David F.
Coman, William B.
Thomson, Scott A.
Moss, Denis J.
Title Novel approach to the formulation of an Epstein-Barr virus antigen-based nasopharyngeal carcinoma vaccine
Journal name Journal of Virology   Check publisher's open access policy
ISSN 0022-538X
1098-5514
Publication date 2010
Year available 2010
Sub-type Article (original research)
DOI 10.1128/JVI.01303-09
Open Access Status DOI
Volume 84
Issue 1
Start page 407
End page 417
Total pages 11
Place of publication Washington, DC United States
Publisher American Society for Microbiology
Collection year 2011
Language eng
Subject 2403 Immunology
2406 Virology
Abstract Epstein-Barr virus (EBV) is associated with several malignant diseases including nasopharyngeal carcinoma (NPC), a common neoplasm throughout southeast Asia. Radiotherapy and chemotherapy can achieve remission, but a reemergence of disease is not uncommon. Therefore, there is a need for specific therapies that target the tumor through the recognition of EBV antigens. In NPC, latent membrane protein 1 (LMP1) and LMP2 offer the best opportunity for specific targeting since they are typically expressed and T-cell determinants in each of these proteins have been defined. We have attempted to maximize the opportunity of incorporating every possible CD4 and CD8 determinant in a single formulation. We have achieved this by generating a scrambled protein incorporating random overlapping peptide sets from EBNA1, LMP1, and LMP2, which was then inserted into a replication-deficient strain of adenovirus (adenovirus scrambled antigen vaccine [Ad- SAVINE]). This report describes the construction of this Ad-SAVINE construct, its utility in generating LMP1 and LMP2 responses in healthy individuals as well as NPC patients, and its capacity to define new epitopes. This formulation could have a role in NPC immunotherapy for all ethnic groups since it has the potential to activate all possible CD4 and CD8 responses within EBNA1 and LMPs. Copyright
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Article (original research)
Collection: School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 15 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 20 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Wed, 27 Nov 2013, 09:00:46 EST by System User on behalf of School of Medicine